1. Eli Lilly and Company (NYSE:LLY)
Number of Hedge Fund Holders: 152
Supplied Share-Price Snapshot: $1,423.45, down 0.62%
Diabetes and Obesity Medicines Drive Another Growth Surge
Eli Lilly and Company (NYSE: LLY) leads the supplied ranking as demand for its diabetes and obesity medicines continues to reshape its financial performance. Mounjaro and Zepbound remain the principal commercial drivers, making treatment uptake, manufacturing capacity, and realized prices especially important to the investment case. Although healthcare policy can affect access and reimbursement, the company’s latest results were primarily a story of expanding medicine volumes.
Third-quarter 2026 revenue increased 39% year over year to $24.4 billion. Volume rose 53%, partly offset by a 15% decline in realized prices, demonstrating that rapid sales growth can coexist with significant pricing pressure. Worldwide Mounjaro revenue reached $10.7 billion, up 65%, while U.S. Zepbound sales increased 48% to $5.3 billion. Those figures establish the scale of the company’s leading products while highlighting the importance of distinguishing patient demand from the revenue earned per treatment.
Management raised full-year 2026 revenue guidance to $91 billion–$92 billion, lifting the midpoint by $5.5 billion. Reported diluted earnings per share increased 16% to $7.22, although the quarter included substantial acquired research and development charges and approximately $900 million in revenue benefits, primarily from $410 million of Jardiance milestones and favorable rebate and discount estimate adjustments. These items matter when assessing repeatable earnings power. Among pharmaceutical growth stocks, the company’s momentum is substantial, but sustaining it requires continued access, adequate supply, and successful management of pricing pressure alongside broader pipeline development.
Ranking Rationale
Eli Lilly and Company (NYSE: LLY) takes first place with 152 hedge fund holders, the highest count in the supplied dataset. Rapid revenue growth and the scale of its diabetes and obesity franchise support its investment profile. The top ranking measures ownership within this selection; it does not establish the stock’s valuation attractiveness or future return.
YOU MUST READ THIS: 10 Best Biotech Stocks Under $10 to Buy Now
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
